Larval zebrafish model for FDA-approved drug repositioning for tobacco dependence treatment.
Ontology highlight
ABSTRACT: Cigarette smoking remains the most preventable cause of death and excess health care costs in the United States, and is a leading cause of death among alcoholics. Long-term tobacco abstinence rates are low, and pharmacotherapeutic options are limited. Repositioning medications approved by the U.S. Food and Drug Administration (FDA) may efficiently provide clinicians with new treatment options. We developed a drug-repositioning paradigm using larval zebrafish locomotion and established predictive clinical validity using FDA-approved smoking cessation therapeutics. We evaluated 39 physician-vetted medications for nicotine-induced locomotor activation blockade. We further evaluated candidate medications for altered ethanol response, as well as in combination with varenicline for nicotine-resp
SUBMITTER: Cousin MA
PROVIDER: S-EPMC3962344 | biostudies-literature | 2014
REPOSITORIES: biostudies-literature
ACCESS DATA